PRESS RELEASE ARCHIVES FROM SEND2PRESS® NEWSWIRE
NOTICE: THIS IS ARCHIVAL CONTENT AND LIKELY OUT OF DATE.
Original editor for Send2Press: Christopher L. Simmons
Health Discovery Corporation Announces Participation in the SCIA Conference
Savannah, Ga, April 7, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin
Board: HDVY) today announced that David Cooper, M.D., Ph.D., President and Chief Medical
Officer of Health Discovery Corporation, was one of the presenters at the Southern California
Investment Association conference on Saturday April 3rd which was held in Orange County, CA.
Dr. Cooper discussed the status of Health Discovery Corporation, a
genomic/proteomic/biotechnology company focused on biomarker and pathway discovery for
diagnostic markers and drug targets.
He indicated that the company is proceeding well with recently signed agreements with MD
Anderson Cancer Center, Stanford University and the University of Miami. These agreements,
which provide joint ownership of the biomarker discovery and/or rights to obtain worldwide
exclusive licenses to the discoveries, are focusing specifically on Prostate Cancer, Leukemia,
AIDS Related Dementia and Lymphatic Insufficiency. Additional relationships are to be announced
He expects the Company to be profitable within about 18 months as their products and client
list continues to grow. Dr. Cooper indicated that whereas most companies in the
genomic/proteomic space are raising upwards of $100 million to fund their research, Health
Discovery Corporation's expected capital requirements will be small in comparison to several of
its competitors in this space because HDC identifies patient-specific commercially important
clinical problems and then establishes relationships with diagnostic and pharmaceutical
companies world-wide to facilitate a solution, whereas, other companies focus on general
discovery without a specific patient or illness in mind.
Health Discovery Corporation is a systems biology oriented biomarker and pathway discovery
company, which uses proprietary advanced mathematical platforms, such as Fractal Genomics
Modeling (FGM) techniques, to help identify and characterize diagnostic targets and therapeutic
candidates. Focusing on disease vs. normal, within complex genomic, proteomic and clinical data
sets, Health Discovery Corporation was established to provide pharmaceutical and diagnostic
companies with a broad range of analytical and decision support solutions to accelerate
effective diagnostic and drug discovery.
Founded in September 2003, the Company has offices in
Texas, Georgia, and California. For more information contact Robert S. Braswell IV of Health
Discovery Corporation +1-866-953-9031 or Info@healthdiscoverycorp.com.
Organization Website: www.healthdiscoverycorp.com
Source of News:
Health Discovery Corporation
Find More Stock Info, Charts, News on OTC BB: HDVY
Yahoo!® Finance (HDVY.OB)
Previous News from Health Discovery Corporation
DISCLAIMER: the above article is believed accurate but not guaranteed, and is based on business news supplied by the organization mentioned and/or quoted in the story. The organization providing the news to Send2Press is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements and public companies should be thoroughly researched before considering material investment. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article.
USE OF THE ABOVE NEWS ARTICLE
News is Copr. © 2004 Neotrope/Send2Press. Reproduction of this news article in any form requires written authorization. You may freely link to this article, or republish the "news release" text version linked to above under "Journalist Tools" without restriction except websites must retain /Send2Press Newswire/ as the source. Sites which offer/sell PR services or newswire services may not reprint our content without express written permission.